Example of Open Access Journal of Clinical Trials format
Recent searches

Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format Example of Open Access Journal of Clinical Trials format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Open Access Journal of Clinical Trials — Template for authors

Publisher: Dove Medical Press
Categories Rank Trend in last 3 yrs
Pharmacology, Toxicology and Pharmaceutics (miscellaneous) #12 of 25 down down by 4 ranks
Pharmacology (medical) #172 of 246 down down by 1 rank
journal-quality-icon Journal quality:
Good
calendar-icon Last 4 years overview: 23 Published Papers | 27 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 05/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 6.4
SJR: 1.187
SNIP: 1.192
open access Open Access

SAGE

Quality:  
High
CiteRatio: 6.1
SJR: 1.333
SNIP: 1.061
open access Open Access

SAGE

Quality:  
High
CiteRatio: 4.8
SJR: 1.164
SNIP: 1.22
open access Open Access

SAGE

Quality:  
High
CiteRatio: 6.3
SJR: 1.196
SNIP: 1.603

Journal Performance & Insights

CiteRatio

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

A measure of average citations received per peer-reviewed paper published in the journal.

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.2

50% from 2019

CiteRatio for Open Access Journal of Clinical Trials from 2016 - 2020
Year Value
2020 1.2
2019 0.8
2018 1.3
2017 0.8
2016 1.2
graph view Graph view
table view Table view

0.223

2% from 2019

SJR for Open Access Journal of Clinical Trials from 2016 - 2020
Year Value
2020 0.223
2019 0.219
2018 0.143
2017 0.192
2016 0.305
graph view Graph view
table view Table view

0.326

84% from 2019

SNIP for Open Access Journal of Clinical Trials from 2016 - 2020
Year Value
2020 0.326
2019 0.177
2018 0.178
2017 0.473
2016 0.699
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has increased by 50% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

insights Insights

  • SJR of this journal has increased by 2% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 84% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Open Access Journal of Clinical Trials

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Dove Medical Press

Open Access Journal of Clinical Trials

Open Access Journal of Clinical Trials is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of clinical trial design, management, legal, ethical and regulatory issues, case r...... Read More

Pharmacology, Toxicology and Pharmaceutics

i
Last updated on
05 Jul 2020
i
ISSN
1179-1519
i
Impact Factor
Medium - 0.638
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Blue faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
unsrt
i
Citation Type
Numbered
[25]
i
Bibliography Example
C. W. J. Beenakker. Specular andreev reflection in graphene. Phys. Rev. Lett., 97(6):067007, 2006.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.2147/OAJCT.S34419
Publication bias: what is it? How do we measure it? How do we avoid it?
Fujian Song1, Lee Hooper, Yoon K. Loke

Abstract:

Publication bias occurs when results of published studies are systematically different from results of unpublished studies. The term "dissemination bias" has also been recommended to describe all forms of biases in the research-dissemination process, including outcome-reporting bias, time-lag bias, gray-literature bias, full-... Publication bias occurs when results of published studies are systematically different from results of unpublished studies. The term "dissemination bias" has also been recommended to describe all forms of biases in the research-dissemination process, including outcome-reporting bias, time-lag bias, gray-literature bias, full-publication bias, language bias, citation bias, and media-attention bias. We can measure publication bias by comparing the results of published and unpublished studies addressing the same question. Following up cohorts of studies from inception and comparing publication levels in studies with statistically significant or "positive" results suggested greater odds of formal publication in those with such results, compared to those without. Within reviews, funnel plots and related statistical methods can be used to indicate presence or absence of publication bias, although these can be unreliable in many circumstances. Methods of avoiding publication bias, by identifying and including unpublished outcomes and unpublished studies, are discussed and evaluated. These include searching without limiting by outcome, searching prospective trials registers, searching informal sources, including meeting abstracts and PhD theses, searching regulatory body websites, contacting authors of included studies, and contacting pharmaceutical or medical device companies for further studies. Adding unpublished studies often alters effect sizes, but may not always eliminate publication bias. The compulsory registration of all clinical trials at inception is an important move forward, but it can be difficult for reviewers to access data from unpublished studies located this way. Publication bias may be reduced by journals by publishing high-quality studies regardless of novelty or unexciting results, and by publishing protocols or full-study data sets. No single step can be relied upon to fully overcome the complex actions involved in publication bias, and a multipronged approach is required by researchers, patients, journal editors, peer reviewers, research sponsors, research ethics committees, and regulatory and legislation authorities. read more read less

Topics:

Publication bias (73%)73% related to the paper, Funnel plot (67%)67% related to the paper
View PDF
178 Citations
open accessOpen access Journal Article DOI: 10.2147/OAJCT.S8172
Clinical data management: Current status, challenges, and future directions from industry perspectives

Abstract:

Correspondence: Zhengwu Lu 1111 Weyburn LN#29, San Jose, CA 95129, USA Tel +1 201 233 0738 Fax +1 201 949 4085 email zhengwu.lu@ieee.org Abstract: To maintain a competitive position, the biopharmaceutical industry has been facing the challenge of increasing productivity both internally and externally. As the product of the cl... Correspondence: Zhengwu Lu 1111 Weyburn LN#29, San Jose, CA 95129, USA Tel +1 201 233 0738 Fax +1 201 949 4085 email zhengwu.lu@ieee.org Abstract: To maintain a competitive position, the biopharmaceutical industry has been facing the challenge of increasing productivity both internally and externally. As the product of the clinical development process, clinical data are recognized to be the key corporate asset and provide critical evidence of a medicine’s efficacy and safety and of its potential economic value to the market. It is also well recognized that using effective technology-enabled methods to manage clinical data can enhance the speed with which the drug is developed and commercialized, hence enhancing the competitive advantage. The effective use of data-capture tools may ensure that high-quality data are available for early review and rapid decision-making. A well-designed, protocol-driven, standardized, site workflow-oriented and documented database, populated via efficient data feed mechanisms, will ensure regulatory and commercial questions receive rapid responses. When information from a sponsor’s clinical database or data warehouse develops into corporate knowledge, the value of the medicine can be realized. Moreover, regulators, payer groups, patients, activist groups, patient advocacy groups, and employers are becoming more educated consumers of medicine, requiring monetary value and quality, and seeking out up-todate medical information supplied by biopharmaceutical companies. All these developments in the current biopharmaceutical arena demand that clinical data management (CDM) is at the forefront, leading change, influencing direction, and providing objective evidence. Sustaining an integrated database or data repository for initial product registration and subsequent postmarketing uses is a long-term process to maximize return on investment for organizations. CDM should be the owner of driving clinical data-cleaning process in consultation with other stakeholders, such as clinical operations, safety, quality assurance, and sites, and responsible for building a knowledge base to add potential value in assisting further study designs or clinical programs. CDM needs to draw on a broad range of skills such as technical, scientific, project management, information technology (IT), systems engineering, and interpersonal skills to tackle, drive, and provide valued service in managing data within the anticipated e-clinical age. Commitment to regulatory compliance is required in this regulated industry; however, a can-do attitude with strong willingness to change and to seek ways to improve CDM functions and processes proactively are essential to continued success and to ensure quality data-driven productivity. read more read less

Topics:

Clinical data management (69%)69% related to the paper, Data management (57%)57% related to the paper
View PDF
69 Citations
open accessOpen access Journal Article DOI: 10.2147/OAJCT.S8270
Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer.

Abstract:

BACKGROUND: Advanced pancreatic cancer carries the poorest prognosis of all gastrointestinal malignancies. Once the tumor has spread beyond the margins of the pancreas, chemotherapy is the major treatment modality offered to patients; however, chemotherapy does not significantly improve survival. OBJECTIVE: Opioid growth fact... BACKGROUND: Advanced pancreatic cancer carries the poorest prognosis of all gastrointestinal malignancies. Once the tumor has spread beyond the margins of the pancreas, chemotherapy is the major treatment modality offered to patients; however, chemotherapy does not significantly improve survival. OBJECTIVE: Opioid growth factor (OGF; [Met(5)]-enkephalin) is a natural peptide that has been shown to inhibit growth of pancreatic cancer in cell culture and in nude mice. The purpose of this study was to evaluate the effects of OGF biotherapy on subjects with advanced pancreatic cancer who failed chemotherapy. METHODS: In a prospective phase II open-labeled clinical trial, 24 subjects who failed standard chemotherapy for advanced pancreatic cancer were treated weekly with OGF 250 µg/kg intravenously. Outcomes measured included clinical benefit, tumor response by radiographic imaging, quality of life, and survival. RESULTS: Clinical benefit response was experienced by 53% of OGF-treated patients compared to historical controls of 23.8% and 4.8% for gemcitabine and 5-fluorouracil (5-FU), respectively. Of the subjects surviving more than eight weeks, 62% showed either a decrease or stabilization in tumor size by computed tomography. The median survival time for OGF-treated patients was three times that of untreated patients (65.5 versus 21 days, p < 0.001). No adverse effects on hematologic or chemistry parameters were noted, and quality of life surveys suggested improvement with OGF. LIMITATIONS: Measurements other than survival were not allowed in control patients, and clinical benefit comparisons were made to historical controls. CONCLUSION: OGF biotherapy improves the clinical benefit and prolongs survival in patients with pancreatic cancer by stabilizing disease or slowing progression. The effects of OGF did not adversely alter patient quality of life. The use of OGF biotherapy at earlier stages of disease or in combination with other chemotherapeutic agents may further improve the outcome of this malignancy. read more read less

Topics:

Pancreatic cancer (56%)56% related to the paper, Gemcitabine (52%)52% related to the paper
View PDF
42 Citations
open accessOpen access Journal Article DOI: 10.2147/OAJCT.S37741
Biology and natural history of human papillomavirus infection

Abstract:

Human papillomavirus (HPV) is one of the most common causes of sexually trans- mitted diseases worldwide. It has been proposed that the great majority of women and men have been infected with HPV at least once during their lifetime. HPV infection is associated with a variety of clinical conditions, ranging from benign lesions... Human papillomavirus (HPV) is one of the most common causes of sexually trans- mitted diseases worldwide. It has been proposed that the great majority of women and men have been infected with HPV at least once during their lifetime. HPV infection is associated with a variety of clinical conditions, ranging from benign lesions to cervical cancer. In most cases, the infection is transient, where most of the individuals are healing, eliminating the virus without the presence of any clinical manifestation. Actually, more than 120 HPV types have been cataloged, of which approximately 40 can infect the mucosa of the anogenital tract and are collectively known as mucosal HPV, which are classified based on their oncogenic potential as either low- or high-risk HPV types. The low-risk HPV type causes benign hyperproliferative lesions or genital warts, with a very limited tendency for malignant progression, while the high-risk HPV type is strongly associated with premalignant and malignant cervical lesions. The HPV cycle initiates when the virus gains access to undifferentiated cells of the basement membrane of the squamous columnar junction epithelium of the ectocervix, after these regions are exposed to mechanical or chemical trauma. The basal cells in the transformation zone retain the ability to differentiate, a property required for virion production. Cervical infection with high-risk HPV typically lasts from 12 to 18 months and in most cases is cleared spontaneously. However, in some women the immune response is insufficient to eliminate the virus, resulting in a persistent, long-term infection that may progress to a malignant lesion. In this review, we discuss the biology and natural history of HPV infection and its association with cervical cancer. read more read less

Topics:

HPV infection (62%)62% related to the paper, Genital warts (61%)61% related to the paper, Cervical cancer (56%)56% related to the paper
View PDF
40 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Open Access Journal of Clinical Trials.

It automatically formats your research paper to Dove Medical Press formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Open Access Journal of Clinical Trials format uses unsrt citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Open Access Journal of Clinical Trials in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Open Access Journal of Clinical Trials guidelines and auto format it.

2. Do you follow the Open Access Journal of Clinical Trials guidelines?

Yes, the template is compliant with the Open Access Journal of Clinical Trials guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Open Access Journal of Clinical Trials?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Open Access Journal of Clinical Trials citation style.

4. Can I use the Open Access Journal of Clinical Trials templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Open Access Journal of Clinical Trials.

5. Can I use a manuscript in Open Access Journal of Clinical Trials that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Open Access Journal of Clinical Trials that you can download at the end.

6. How long does it usually take you to format my papers in Open Access Journal of Clinical Trials?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Open Access Journal of Clinical Trials.

7. Where can I find the template for the Open Access Journal of Clinical Trials?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Open Access Journal of Clinical Trials's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Open Access Journal of Clinical Trials's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Open Access Journal of Clinical Trials an online tool or is there a desktop version?

SciSpace's Open Access Journal of Clinical Trials is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Open Access Journal of Clinical Trials?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Open Access Journal of Clinical Trials?”

11. What is the output that I would get after using Open Access Journal of Clinical Trials?

After writing your paper autoformatting in Open Access Journal of Clinical Trials, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Open Access Journal of Clinical Trials's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Open Access Journal of Clinical Trials?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Open Access Journal of Clinical Trials. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Open Access Journal of Clinical Trials?

The 5 most common citation types in order of usage for Open Access Journal of Clinical Trials are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Open Access Journal of Clinical Trials?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Open Access Journal of Clinical Trials's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Open Access Journal of Clinical Trials in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Open Access Journal of Clinical Trials Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Open Access Journal of Clinical Trials formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template